Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
ATP Binding Cassette Transporter, Subfamily B, Member 1
Animals
Antineoplastic Agents
/ chemistry
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Drug Delivery Systems
/ methods
Drug Resistance, Multiple
/ drug effects
Drug Resistance, Neoplasm
/ drug effects
Drug Therapy, Combination
Female
Humans
MCF-7 Cells
Mice
Mice, Inbred BALB C
Mice, Nude
Nanoparticles
/ chemistry
Neoplasm Metastasis
Paclitaxel
/ pharmacology
Particle Size
Pharmaceutical Preparations
Wound Healing
Xanthones
/ pharmacology
Xenograft Model Antitumor Assays
Metastasis
Multidrug resistance
Nano-combination therapy
Synergistic anti-cancer
Targeted cancer therapy
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
received:
16
05
2020
accepted:
25
08
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
7
7
2021
Statut:
epublish
Résumé
Poor targeting and penetration of chemotherapy drugs in solid tumors, and the development of resistance to chemotherapeutic agents are currently hindering the therapy of breast cancer; meanwhile, breast cancer metastasis is one of the leading causes of death in breast cancer patients. With the development of nanotechnology, nanomaterials have been widely used in tumor therapy. A multi-functional nano-platform containing gambogic acid (GA) and paclitaxel (PTX) was characterized by a small size, high encapsulation efficiency, slow release, long systemic circulation time in vivo, showed good targeting and penetrability to tumor tissues and tumor cells, and exhibited higher anti-tumor effect and lower systemic toxicity in BALB/c mice bearing 4T1 tumor. GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments. Our data described the better recognition and penetration of tumor cells of R9dGR-modified versatile nanosystems containing GA and PTX, which exerted one stone three birds clinical therapeutic efficacy of multifunctionality.
Sections du résumé
BACKGROUND
BACKGROUND
Poor targeting and penetration of chemotherapy drugs in solid tumors, and the development of resistance to chemotherapeutic agents are currently hindering the therapy of breast cancer; meanwhile, breast cancer metastasis is one of the leading causes of death in breast cancer patients. With the development of nanotechnology, nanomaterials have been widely used in tumor therapy.
RESULTS
RESULTS
A multi-functional nano-platform containing gambogic acid (GA) and paclitaxel (PTX) was characterized by a small size, high encapsulation efficiency, slow release, long systemic circulation time in vivo, showed good targeting and penetrability to tumor tissues and tumor cells, and exhibited higher anti-tumor effect and lower systemic toxicity in BALB/c mice bearing 4T1 tumor. GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments.
CONCLUSION
CONCLUSIONS
Our data described the better recognition and penetration of tumor cells of R9dGR-modified versatile nanosystems containing GA and PTX, which exerted one stone three birds clinical therapeutic efficacy of multifunctionality.
Identifiants
pubmed: 32887626
doi: 10.1186/s12951-020-00681-8
pii: 10.1186/s12951-020-00681-8
pmc: PMC7650261
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Antineoplastic Agents
0
Pharmaceutical Preparations
0
Xanthones
0
gambogic acid
8N585K83U2
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Références
Biomaterials. 2013 May;34(16):4137-4149
pubmed: 23453200
ACS Nano. 2019 Dec 24;13(12):13620-13626
pubmed: 31800203
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679654
Drug Des Devel Ther. 2018 Apr 05;12:743-756
pubmed: 29670331
Clin Cancer Res. 2005 Jun 1;11(11):4136-43
pubmed: 15930349
Clin Cancer Res. 2005 Jan 1;11(1):298-305
pubmed: 15671559
Pharmazie. 2006 May;61(5):375-86
pubmed: 16724531
Neuropharmacology. 2014 Jan;76 Pt A:175-83
pubmed: 23978385
Colloids Surf B Biointerfaces. 2015 May 1;129:175-82
pubmed: 25851582
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7159-E7168
pubmed: 28784776
Biomaterials. 2016 Jul;94:70-83
pubmed: 27105438
Biochem Biophys Res Commun. 2018 May 5;499(2):374-380
pubmed: 29577899
Eur J Pharm Sci. 2013 May 13;49(2):220-6
pubmed: 23501055
J Ethnopharmacol. 2008 May 22;117(3):433-8
pubmed: 18384990
Anticancer Drugs. 2014 Jul;25(6):663-72
pubmed: 24583771
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Cancer Biother Radiopharm. 2012 Jun;27(5):299-306
pubmed: 22444164
Curr Cancer Drug Targets. 2014;14(1):91-103
pubmed: 24245692
Cell Tissue Res. 2013 Apr;352(1):123-31
pubmed: 22729488
Adv Healthc Mater. 2015 Apr 2;4(5):748-59
pubmed: 25522298
Cancer Lett. 2012 Jun 28;319(2):203-213
pubmed: 22306340
Eur J Pharm Sci. 2018 Nov 1;124:240-248
pubmed: 30071282
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Chem Biol Interact. 2015 Jun 25;235:76-84
pubmed: 25824409
Colloids Surf B Biointerfaces. 2014 Jan 1;113:43-50
pubmed: 24060929
Cancer Lett. 2007 Oct 28;256(2):259-66
pubmed: 17693016
Indian J Pharm Sci. 2013 Sep;75(5):591-8
pubmed: 24403661
Acta Pharmacol Sin. 2012 Apr;33(4):531-41
pubmed: 22426696
Eur J Pharm Biopharm. 2013 Feb;83(2):266-74
pubmed: 23089310
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
BMC Bioinformatics. 2010 Dec 14;11 Suppl 11:S6
pubmed: 21172056
Theranostics. 2016 Jan 01;6(2):177-91
pubmed: 26877777
Pharm Res. 2018 Apr 26;35(7):130
pubmed: 29700620
Biomaterials. 2014 Aug;35(26):7654-65
pubmed: 24927684
Curr Cancer Drug Targets. 2003 Feb;3(1):1-19
pubmed: 12570657
J Natl Cancer Inst. 1993 Oct 20;85(20):1685-90
pubmed: 8105099
Pharmacol Res. 2016 Sep;111:577-591
pubmed: 27461138
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8
pubmed: 11087855
Tumour Biol. 2016 Aug;37(8):10643-52
pubmed: 26867766
J Biomed Mater Res A. 2014 Dec;102(12):4262-75
pubmed: 24488670
Int J Nanomedicine. 2019 Mar 22;14:2029-2053
pubmed: 30962686
Biochem Cell Biol. 2008 Oct;86(5):386-95
pubmed: 18923540
Int J Pharm. 2015 Nov 30;495(2):840-8
pubmed: 26407923
Chin Med J (Engl). 2013;126(9):1642-6
pubmed: 23652044
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Oncol. 2018 Apr;11(2):426-435
pubmed: 29475139
Int J Nanomedicine. 2019 Aug 02;14:6179-6195
pubmed: 31447559
Pharmacol Ther. 2016 Jul;163:94-108
pubmed: 27063403
Immunol Allergy Clin North Am. 2017 Nov;37(4):679-693
pubmed: 28965634
Pharm Pat Anal. 2014 Mar;3(2):199-215
pubmed: 24588596
Anticancer Res. 1993 Jan-Feb;13(1):93-6
pubmed: 8097392
Mol Carcinog. 2015 Jun;54 Suppl 1:E13-25
pubmed: 24532189
Lung Cancer. 1995 Apr;12 Suppl 1:S163-72
pubmed: 7551925
Molecules. 2018 Oct 22;23(10):
pubmed: 30360368
Drug Deliv. 2018 Nov;25(1):757-765
pubmed: 29528244
Naunyn Schmiedebergs Arch Pharmacol. 2018 May;391(5):551-560
pubmed: 29546614
Anticancer Agents Med Chem. 2012 Oct 1;12(8):994-1000
pubmed: 22339063